NAS:CRBP (USA) Also Trade In: Germany UK

Corbus Pharmaceuticals Holdings Inc $ 1.95 -0.02 (-1.02%)

Volume:
13,147,197
Avg Vol (1m):
8,937,128
Market Cap $:
163.87 Mil
Enterprise Value $:
108.18 Mil
P/E (TTM):
0.00
P/B:
5.46
Warning! GuruFocus has detected 5 Severe warning signs with CRBP. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Corbus Pharmaceuticals Holdings Inc () from 2014 to Jan 28 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Corbus Pharmaceuticals stock (CRBP) PE ratio as of Jan 28 2021 is 0. More Details

Corbus Pharmaceuticals PE Ratio (TTM) Chart

EMBED

Corbus Pharmaceuticals PE Ratio (TTM) Historical Data

Total 1259
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Corbus Pharmaceuticals PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-01-280.0 2020-11-260.0
2021-01-270.0 2020-11-250.0
2021-01-260.0 2020-11-240.0
2021-01-250.0 2020-11-230.0
2021-01-220.0 2020-11-200.0
2021-01-210.0 2020-11-190.0
2021-01-200.0 2020-11-180.0
2021-01-190.0 2020-11-170.0
2021-01-180.0 2020-11-160.0
2021-01-150.0 2020-11-130.0
2021-01-140.0 2020-11-120.0
2021-01-130.0 2020-11-110.0
2021-01-120.0 2020-11-100.0
2021-01-110.0 2020-11-090.0
2021-01-080.0 2020-11-060.0
2021-01-070.0 2020-11-050.0
2021-01-060.0 2020-11-040.0
2021-01-050.0 2020-11-030.0
2021-01-040.0 2020-11-020.0
2021-01-010.0 2020-10-300.0
2020-12-310.0 2020-10-290.0
2020-12-300.0 2020-10-280.0
2020-12-290.0 2020-10-270.0
2020-12-280.0 2020-10-260.0
2020-12-250.0 2020-10-230.0
2020-12-240.0 2020-10-220.0
2020-12-230.0 2020-10-210.0
2020-12-220.0 2020-10-200.0
2020-12-210.0 2020-10-190.0
2020-12-180.0 2020-10-160.0
2020-12-170.0 2020-10-150.0
2020-12-160.0 2020-10-140.0
2020-12-150.0 2020-10-130.0
2020-12-140.0 2020-10-120.0
2020-12-110.0 2020-10-090.0
2020-12-100.0 2020-10-080.0
2020-12-090.0 2020-10-070.0
2020-12-080.0 2020-10-060.0
2020-12-070.0 2020-10-050.0
2020-12-040.0 2020-10-020.0
2020-12-030.0 2020-10-010.0
2020-12-020.0 2020-09-300.0
2020-12-010.0 2020-09-290.0
2020-11-300.0 2020-09-280.0
2020-11-270.0 2020-09-250.0

Corbus Pharmaceuticals PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325414 NAICS : 2834
Traded in other countries 337.Germany 0SZI.UK CRBP.USA
Address 500 River Ridge Drive, Second Floor, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.